Patent Application for Whitening Cosmetic Composition with Artemisinic Acid
Summary
The USPTO has published a patent application (US20260083657A1) for a whitening cosmetic composition containing artemisinic acid, nicotinamide, and/or glutathione. The application, filed by Yunnan Botanee Bio-Technology Group Co., Ltd., describes a formulation designed to inhibit melanin production and reduce skin irritation.
What changed
This document is a published patent application, not a regulatory rule or guidance. It details a novel cosmetic composition intended for skin whitening, featuring artemisinic acid combined with nicotinamide and/or glutathione. The inventors claim this formulation enhances melanin inhibition, improves the solubility of artemisinic acid, and reduces local skin irritation, aiming for synergistic whitening effects and better skin absorption.
As a patent application, it does not impose immediate regulatory obligations. However, it signifies potential future product development and market entry in the cosmetics sector. Companies involved in cosmetic manufacturing, particularly those focusing on skin lightening products, should be aware of this filing as it may indicate emerging technologies or competitive intellectual property in the field.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION WITH WHITENING EFFECT AND APPLICATION THEREOF IN COSMETICS
Application US20260083657A1 Kind: A1 Mar 26, 2026
Assignee
Yunnan Botanee Bio-Technology Group Co., Ltd.
Inventors
Yichun WANG, Feifei WANG, Liping QU, Yanzhen SHEN, Zuding WANG, Qiongfen WU, Lijuan YAN, Zhaoxiang YANG, Xiao MA, Zhenyu GUO
Abstract
A composition with a whitening effect includes artemisinic acid, and further includes nicotinamide and/or glutathione. The artemisinic acid is creatively compounded with the nicotinamide and/or the glutathione to inhibit generation or transfer of melanin in all directions at multiple angles through different approaches or mechanisms. The composition can significantly inhibit activity of tyrosinase and inhibit production of the melanin, and various active ingredients are complemented with each other to achieve a synergistic effect. Meanwhile, the composition can also enhance water solubility of the artemisinic acid and reduce local irritant toxicity caused by insolubility of the artemisinic acid to enable the artemisinic acid to have good water solubility and low local irritant toxicity while achieving the whitening effect, thereby promoting deep absorption by the skin.
CPC Classifications
A61K 8/64 A61K 8/36 A61K 8/675 A61Q 19/02
Filing Date
2025-10-28
Application No.
19372192
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.